Marrow ablative therapy has been given to pediatric @entity1 with a variety of disseminated @entity5 . Eight @entity1 with advanced @entity521 received autologous marrow reinfusion after intensive therapy. Three of eight are in continus complete remission for 7 to 60 months. An additional four @entity1 received allogeneic marrow transplantation and two remain in continuous complete response at 21 and 39 months. Intensive therapy and autologous marrow reinfusion have been applied to @entity2828 , but only preliminary results are available. Six @entity1 with disseminated @entity980 and extra-osseous @entity2828 received conventional chemotherapy followed by sequential hemi-body irradiation. Four of six @entity1 received autologous marrow rescue. Their median disease-free survival is 17 months. This preliminary experience demonstrates the feasibility of using marrow ablative therapy with autologous marrow transplantation in the treatment of pediatric @entity5 . Continuing Phase II studies are required to substantiate its efficacy.

Magna-field irradiation and autologous marrow rescue in the tratment of pediatric XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity2828 :: ('MESH:D012512', 'Disease') :: ["Ewing's sarcoma"] @entity5 :: ('MESH:D009369', 'Disease') :: ['solid tumors', 'tumors'] @entity521 :: ('MESH:D009447', 'Disease') :: ['neuroblastoma'] @entity980 :: ('MESH:D012208', 'Disease') :: ['rhabdomyosarcoma']
@entity5 :: (MESH:D009369,Disease) :: ['solid tumors']
